FYR Diagnostics
PrivateLast Round
Grant
Nov 19, 2025
Total Funding Raised
$3.57M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
FYR Diagnostics operates in Healthcare & Life Sciences and is based in Missoula, Montana. Its latest recorded funding round was a Grant round in November 2025.
FYR Diagnostics is a biotechnology company that develops biomarker detection technology and AI-enabled multi-omic insights to advance precision medicine and diagnostic solutions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
FYR Diagnostics Comparables
Compare FYR Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeuroDex | 85% | |
| NanoSomiX, Inc. | 84% | |
| Exosomics S.p.A. | 82% |
For institutional investors. Book with your work email.
FYR Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 19, 2025 | ||||
| VC Round | Sep 24, 2025 | ||||
| Grant | Aug 15, 2021 | ||||
| Grant | Dec 1, 2020 | ||||
| Grant | Oct 10, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
FYR Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| National Institute on Drug Abuse | Grant |
| NIH RADx | Grant |
| Yuvaan Tiwari Foundation | VC Round |
| Two Bear Capital | VC Round, Seed |
| National Institute of Neurological Disorders and Stroke (NINDS) | Grant |
| The Sontag Foundation | VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 10, 2026
Barbara K. Zehentner appointed as new COO.
- Nov 19, 2025
$2M grant received from the National Cancer Institute.
For institutional investors. Book with your work email.
FYR Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about FYR Diagnostics's valuation, stock price, and market status.
Is FYR Diagnostics a public or private company?
FYR Diagnostics is a private company.
What is the current stock price of FYR Diagnostics?
FYR Diagnostics is a private company, so its shares have no public market price. Caplight tracks FYR Diagnostics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is FYR Diagnostics worth (valuation)?
Valuation information for FYR Diagnostics is not publicly available.
Can I buy FYR Diagnostics stock?
FYR Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was FYR Diagnostics's last funding round?
FYR Diagnostics's most recent funding round was Grant on November 19, 2025.
Who are the main investors in FYR Diagnostics?
Key investors in FYR Diagnostics include National Cancer Institute, NIH RADx, Two Bear Capital, National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Neurological Disorders and Stroke.
Will FYR Diagnostics IPO soon?
No public IPO plans have been announced for FYR Diagnostics.
How can I track FYR Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades in FYR Diagnostics's shares on secondary markets.